Viridian Therapeutics shares surged 10.8% in pre-market trading after its drug for treating thyroid eye disease received approval from the U.S. Food and Drug Administration.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Coherent (COHR.US) launches PhotonLink integrated optical platform targeting next-generation AI data centers
Coherent (COHR.US) announced the launch of its integrated photonics platform, PhotonLink, on Monday.
Goldman Sachs: 5% yield on US Treasury bonds is attractive, but going long on AI computing power is even better.
With long-term U.S. Treasury yields hovering around 5%, government bonds have become attractive again. However, according to a Goldman Sachs executive, AI infrastructure still offers better opportunities.
Bank of Canada Issues Strongest Stagflation Warning: Tariffs May Push Q4 Growth Below 1%, High Oil Prices Intensify Inflation
Bank of Canada Governor Macklem stated on Monday that a new round of U.S. tariffs could halve Canada’s fourth-quarter economic growth, dropping it below 1%, while annual inflation will remain at 3%, exceeding the 2% target. He added that if oil prices continue to hover around $100 per barrel, prices could be pushed even higher. Macklem said that if inflation is manageable, he does not want to raise interest rates; however, if inflation exceeds expectations, he also does not want to react too slowly.
Crypto prices
More
